

Michela Cini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2241915/publications.pdf>

Version: 2024-02-01

41
papers

1,224
citations

331538

21
h-index

360920

35
g-index

41
all docs

41
docs citations

41
times ranked

1191
citing authors

#	ARTICLE	IF	CITATIONS
1	Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. <i>Blood</i> , 2002, 100, 2272-2272.	0.6	156
2	D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2005, 94, 969-974.	1.8	96
3	Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 955-961.	1.9	88
4	Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2194-2201.	1.9	68
5	Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2010, 104, 402-409.	1.8	58
6	The Wells rule and D-dimer for the diagnosis of isolated distal deep vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2264-2269.	1.9	58
7	Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. <i>British Journal of Haematology</i> , 2006, 134, 227-232.	1.2	53
8	D-dimer for the diagnosis of upper extremity deep and superficial venous thrombosis. <i>Thrombosis Research</i> , 2015, 135, 673-678.	0.8	48
9	D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2011, 105, 837-845.	1.8	43
10	A new rapid bedside assay for d-dimer measurement (Simplify d-dimer) in the diagnostic work-up for deep vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2681-2683.	1.9	42
11	D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. <i>Thrombosis Research</i> , 2008, 122, 610-617.	0.8	40
12	Age and gender specific cut-off values to improve the performance of d-dimer assays to predict the risk of venous thromboembolism recurrence. <i>Internal and Emergency Medicine</i> , 2013, 8, 229-236.	1.0	38
13	The role of D-dimer and residual venous obstruction in recurrence of venous thromboembolism after anticoagulation withdrawal in cancer patients. <i>Haematologica</i> , 2005, 90, 713-5.	1.7	36
14	Multicenter evaluation of a new quantitative highly sensitive D-dimer assay, the Hemosil® D-dimer HS 500, in patients with clinically suspected venous thromboembolism. <i>Thrombosis Research</i> , 2010, 125, 398-401.	0.8	34
15	A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1167-1174.	0.8	32
16	Thalidomide+dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. <i>European Journal of Haematology</i> , 2010, 84, 484-492.	1.1	31
17	Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study. <i>Haematologica</i> , 2008, 93, 900-907.	1.7	30
18	Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: A prospective, randomised study comparing two doses of parnaparin (BAFLUX STUDY). <i>Thrombosis Research</i> , 2009, 124, 667-671.	0.8	29

#	ARTICLE	IF	CITATIONS
19	Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. <i>Thrombosis Research</i> , 2003, 109, 333-339.	0.8	27
20	Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 392-394.	1.0	24
21	Thrombophilic risk factors and peripheral arterial disease severity. <i>Thrombosis and Haemostasis</i> , 2010, 104, 71-77.	1.8	23
22	D-dimer use for deep venous thrombosis exclusion in elderly patients: a comparative analysis of three different approaches to establish cut-off values for an assay with results expressed in D-dimer units. <i>International Journal of Laboratory Hematology</i> , 2014, 36, 541-547.	0.7	21
23	A new rapid bedside assay for quantitative testing of D-Dimer (Cardiac D-Dimer) in the diagnostic work-up for deep vein thrombosis. <i>Thrombosis Research</i> , 2003, 111, 149-153.	0.8	19
24	D-dimer, FVIII and thrombotic burden in the acute phase of deep vein thrombosis in relation to the risk of post-thrombotic syndrome. <i>Thrombosis Research</i> , 2014, 134, 320-325.	0.8	19
25	DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 214-222.	0.7	18
26	Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. <i>Haematologica</i> , 2004, 89, 1347-51.	1.7	17
27	Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 229-236.	0.7	12
28	The F11 rs2289252 polymorphism is associated with FXI activity levels and APTT ratio in women with thrombosis. <i>Thrombosis Research</i> , 2012, 130, 563-564.	0.8	9
29	Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms. <i>Blood</i> , 2013, 122, 2555-2561.	0.6	9
30	Inherited and acquired thrombophilic alterations in patients with superficial vein thrombosis of lower limbs. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1194-1196.	1.8	9
31	Measurement of factor XIII (FXIII) activity by an automatic ammonia release assay using iodoacetamide blank-procedure: no more overestimation in the low activity range and better detection of severe FXIII deficiencies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 805-9.	1.4	7
32	An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 309-315.	0.7	6
33	G20210A Prothrombin Mutation and Critical Limb Ischaemia in Patients with Peripheral Arterial Disease. <i>European Journal of Vascular and Endovascular Surgery</i> , 2009, 38, 113-117.	0.8	4
34	Diagnostic Accuracy of a New D-Dimer Assay (Sclavo Auto-Dimer) for Exclusion of Deep Vein Thrombosis in Symptomatic Outpatients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 221-228.	0.7	4
35	Unprovoked or provoked venous thromboembolism: not the prevalent criterion to decide on anticoagulation extension in clinical practice of various countries—the prospective, international, observational WHITE study. <i>Internal and Emergency Medicine</i> , 2022, 17, 71-82.	1.0	4
36	Influence of low-density lipoprotein (LDL) receptor-related protein and ABO blood group genotypes on factor XI levels. <i>Thrombosis and Haemostasis</i> , 2008, 99, 789-790.	1.8	3

#	ARTICLE	IF	CITATIONS
37	No early signs of atherosclerotic alterations in carriers of inherited thrombophilia. <i>European Journal of Internal Medicine</i> , 2010, 21, 273-277.	1.0	3
38	Evaluation of a chemiluminescent immunoassay, the HemosIL AcuStar D-Dimer, in outpatients with clinically suspected deep venous thrombosis. <i>International Journal of Laboratory Hematology</i> , 2015, 37, e172-e174.	0.7	2
39	Anticoagulation Duration After First Venous Thromboembolism: Real-Life Data From the International, Observational WHITE Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110494.	0.7	2
40	The influence of VKORC1 3730 G > A polymorphism on warfarin dose: reply. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1045-1045.	0.8	1
41	Thrombotic burden, D-dimer levels and complete compression ultrasound for diagnosis of acute symptomatic deep vein thrombosis of the lower limbs. <i>Thrombosis Research</i> , 2022, 213, 163-169.	0.8	1